<?xml version="1.0" encoding="UTF-8"?>
<p>HCV and CKD are remarkable public health problems worldwide. The overall mean prevalence of CKD in the general population is around 13.4% (stages 1 to 5) and 10.6% (stages 3 to 5). Traditional risk factors for developing chronic renal disease (diabetes mellitus, arterial hypertension, smoking, weight overload) do not explain completely the current prevalence of chronic kidney disease in the adult general population of industrialized world. Chronic infections by hepatotropic viruses (hepatitis B and hepatitis C viruses) or human immunodeficiency virus (HIV) are non-traditional, but modifiable causes of chronic kidney disease [
 <xref rid="B6-pathogens-08-00176" ref-type="bibr">6</xref>,
 <xref rid="B7-pathogens-08-00176" ref-type="bibr">7</xref>]. The adverse impact of chronic HCV on chronic kidney disease suggests the antiviral therapy of all HCV-infected patients, regardless of their stage of liver and kidney injury [
 <xref rid="B3-pathogens-08-00176" ref-type="bibr">3</xref>].
</p>
